The adeno-associated viral (AAV) vector has emerged as an attractive vector for gene therapy applications. Development of AAV vectors with enhanced gene transduction efficiency is important to ease the burden of AAV production and minimize potential immune responses. Rational mutations on AAV capsids have gained attention as a simple method of enhancing AAV transduction efficiency. A single-amino acid mutation, K137R, on AAV1 and AAV8 was recently reported to increase liver transgene expression by 5–10-fold. To determine whether the same mutation on other AAV serotypes would result in similar gene enhancement effects, K137R mutants were generated on AAV7, AAV8, and AAV9, and their effects were evaluated in vivo. Two reporter genes were utilized: the nuclear LacZ gene driven by the cytomegalovirus promoter and the luciferase gene driven by the CB promoter. Surprisingly, we found no difference in luciferase gene expression in the liver or other tissues using either the wild-type AAV8 capsid or AAV8-K137R. LacZ gene expression in the liver by AAV8-K137R was about onefold higher than that of wild-type AAV8. However, no difference was found in other tissues, such as skeletal muscle and cardiac muscle. In addition, no difference was found in transgene expression with either AAV7-K137R or AAV9-K137R mutants. Our results indicated that the K137R mutation on AAV7, AAV8, and AAV9 had minimal to no effect on transduction efficiency in vivo.
Get full access to this article
View all access options for this article.
References
1.
AsokanA., ConwayJ.C., PhillipsJ.L., et al. (2010). Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol., 28, 79–82.
2.
AyusoE., MingozziF., MontaneJ., et al. (2010). High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther., 17, 503–510.
3.
BishL.T., MorineK., SleeperM.M., et al. (2008). Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther., 19, 1359–1368.
4.
BowlesD.E., McpheeS.W., LiC., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther., 20, 443–455.
5.
DalkaraD., ByrneL.C., LeeT., et al. (2011). Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther., 19, 176–181.
6.
DayaS., and BernsK.I. (2008). Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev., 21, 583–593.
7.
GabrielN., HareendranS., SenD., et al. (2013). Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Hum. Gene Ther. Methods, 24, 80–93.
8.
GaoG.P., AlviraM.R., WangL., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA, 99, 11854–11859.
9.
GriegerJ.C., and SamulskiR.J. (2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol., 507, 229–254.
10.
HauswirthW.W., AlemanT.S., KaushalS., et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther., 19, 979–990.
11.
InagakiK., FuessS., StormT.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther., 14, 45–53.
12.
KaplittM.G., FeiginA., TangC., et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, 369, 2097–2105.
13.
KornegayJ.N., LiJ., BoganJ.R., et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol. Ther., 18, 1501–1508.
14.
MaguireA.M., HighK.A., AuricchioA., et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet, 374, 1597–1605.
15.
MaguireA.M., SimonelliF., PierceE.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358, 2240–2248.
16.
MannoC.S., ChewA.J., HutchisonS., et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101, 2963–2972.
17.
MendellJ.R., CampbellK., Rodino-KlapacL., et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med., 363, 1429–1437.
18.
MuellerC., and FlotteT.R. (2008). Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther., 15, 858–863.
19.
MuzyczkaN., and WarringtonK.H.Jr., (2005). Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther., 16, 408–416.
20.
NakaiH., FuessS., StormT.A., et al. (2005). Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol., 79, 214–224.
21.
NathwaniA.C., TuddenhamE.G., RangarajanS., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365, 2357–2365.
22.
PangJ.J., DaiX., BoyeS.E., et al. (2011). Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol. Ther., 19, 234–242.
23.
Petrs-SilvaH., DinculescuA., LiQ., et al. (2009). High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol. Ther., 17, 463–471.
24.
QiaoC., LiJ., ZhuT., et al. (2005). Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc. Natl. Acad. Sci. USA, 102, 11999–12004.
25.
QiaoC., YuanZ., LiJ., et al. (2011). Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther., 4, 403–410.
26.
QiaoC., YuanZ., LiJ., et al. (2012). Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum. Gene Ther. Methods, 23, 29–37.
27.
SchafferD.V., and MaheshriN. (2004). Directed evolution of AAV mutants for enhanced gene delivery. Conf. Proc. IEEE Eng. Med. Biol. Soc., 5, 3520–3523.
28.
SenD., BalakrishnanB., GabrielN., et al. (2013a). Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci. Rep., 3, 1832.
29.
SenD., GadkariR.A., SudhaG., et al. (2013b). Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum. Gene Ther. Methods, 24, 104–116.
30.
ThomasC.E., StormT.A., HuangZ., and KayM.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol., 78, 3110–3122.
31.
WangB., LiJ., and XiaoX. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA, 97, 13714–13719.
32.
WangZ., MaH.I., LiJ., et al. (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther., 10, 2105–2111.
33.
WangZ., ZhuT., QiaoC., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol., 23, 321–328.
34.
WuZ., AsokanA., and SamulskiR.J. (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther., 14, 316–327.
35.
XiaoX., LiJ., and SamulskiR.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol., 72, 2224–2232.
36.
XuL., DalyT., GaoC., et al. (2001). CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther., 12, 563–573.
37.
YangL., JiangJ., DrouinL.M., et al. (2009). A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. USA, 106, 3946–3951.
38.
ZhongL., LiB., JayandharanG., et al. (2008a). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology, 381, 194–202.
39.
ZhongL., LiB., MahC.S., et al. (2008b). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA, 105, 7827–7832.
40.
ZhongL., ZhaoW., WuJ., et al. (2007). A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol. Ther., 15, 1323–1330.
41.
ZhuT., ZhouL., MoriS., et al. (2005). Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation, 112, 2650–2659.
42.
ZincarelliC., SoltysS., RengoG., and RabinowitzJ.E. (2008). Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther., 16, 1073–1080.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
